Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ENROLLMENT IN THE ONGOING PHASE 1 DOSE ESCALATION ACESOT-1051 TRIAL OF ORAL WEE1 INHIBITOR APR-1051 IS ACCELERATING AS DOSE ESCALATION ADVANCES

APREA THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

NEXT CLINICAL DATA UPDATE FROM THE ONGOING PHASE 1 DOSE ESCALATION ACESOT-1051 TRIAL ANTICIPATED AT A MEDICAL MEETING IN Q4 2026, PROVIDING A NEAR-TERM OPPORTUNITY TO DEMONSTRATE CONTINUED CLINICAL PROGRESS WITH APR-1051 ENROLLMENT IN ACESOT-1051 IS ACCELERATING AS THE COMPANY ADVANCES DOSE ESCALATION AND AMASSES THE CLINICAL DATA NEEDED TO INFORM DOSE SELECTION AND SUBSEQUENT DEVELOPMENT APREA PLANS TO ADVANCE APR-1051 IN UTERINE SEROUS CARCINOMA (USC) AND CYCLIN EOVEREXPRESSING PLATINUM-RESISTANT OVARIAN CANCER (PROC) WHILE ALSO EVALUATING COMBINATION REGIMENS WITH STANDARD OF CARE IN HPV-POSITIVE HEAD AND NECK CANCER AND COLORECTAL CANCER, UTILIZING DOSE LEVELS THAT HAVE SHOWN SINGLE-AGENT ACTIVITY AND CLEARED SAFETY REVIEW THE EXPANDED DEVELOPMENT STRATEGY BUILDS ON EMERGING SINGLE-AGENT ACTIVITY AND POSITIONS APR-1051 ACROSS BIOMARKER-DEFINED INDICATIONS WHERE WEE1 INHIBITION MAY ADDRESS SIGNIFICANT UNMET MEDICAL NEED DOYLESTOWN, PA., JULY 30, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY PROVIDED AN UPDATE ON THE ONGOING PHASE 1 DOSE ESCALATION ACESOT-1051 TRIAL OF ITS ORAL WEE1 INHIBITOR APR-1051.

APREA THERAPEUTICS PROVIDES ACESOT-1051 PROGRAM UPDATE FOR WEE1 INHIBITOR APR-1051: ACCELERATING AND EXPANDING ENROLLMENT. CLINICAL DATA PRESENTATION PLANNED FOR Q4 2026

PRESENTATION HIGHLIGHTS EARLY CLINICAL ACTIVITY FROM ACESOT-1051, INCLUDING PARTIAL RESPONSES AND STABLE DISEASE IN PATIENTS ACROSS MULTIPLE TUMOR TYPES MANAGEABLE TOLERABILITY CONFIRMED ACROSS COHORTS PATIENT EXPANSION INTO UTERINE SEROUS CARCINOMA AND PLATINUM-RESISTANT OVARIAN CANCER UNDERWAY; DOSE ESCALATION AND BACKFILL EXPANSION EXPECTED TO COMPLETE Q2 2027 DOYLESTOWN, PA., JUNE 01, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, ANNOUNCES THE PRESENTATION OF A POSTER EARLY RESULTS FROM THE FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 INHIBITOR APR-1051 IN PATIENTS WITH ADVANCED SOLID TUMORS (ACESOT-1051) ON MAY 30 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2026 ANNUAL MEETING, TAKING PLACE IN CHICAGO, ILLINOIS.

APREA THERAPEUTICS PRESENTS UPDATED PHASE 1 DATA ON WEE1 INHIBITOR APR-1051 AT ASCO 2026, DEMONSTRATING EARLY MONOTHERAPY ACTIVITY AND MANAGEABLE TOLERABILITY IN ADVANCED SOLID TUMORS

DOYLESTOWN, PA., MAY 13, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE.

APREA THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

DOYLESTOWN, PA., APRIL 21, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY ANNOUNCED THE ACCEPTANCE OF AN ABSTRACT EARLY RESULTS FROM THE FIRST-IN-HUMAN PHASE 1 STUDY OF WEE1 INHIBITOR APR-1051 IN PATIENTS WITH ADVANCED SOLID TUMORS (ACESOT-1051) AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, TO TAKE PLACE MAY 29 - JUNE 2, 2026, IN CHICAGO, IL.

APREA THERAPEUTICS TO PROVIDE CLINICAL UPDATE ON ACESOT-1051 PHASE 1 TRIAL EVALUATING WEE1 INHIBITOR, APR-1051, AT ASCO 2026 ANNUAL MEETING

DOYLESTOWN, PA., APRIL 01, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED OVERSUBSCRIBED PRIVATE PLACEMENT FINANCING.

APREA THERAPEUTICS ANNOUNCES CLOSING OF OVERSUBSCRIBED $30 MILLION PRIVATE PLACEMENT

FINANCING LED BY SOLEUS CAPITAL WITH PARTICIPATION FROM VESTAL POINT CAPITAL, SQUADRON CAPITAL MANAGEMENT AND ADDITIONAL NEW AND EXISTING INVESTORS DOYLESTOWN, PA., MARCH 30, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SECURITIES PURCHASE AGREEMENT FOR AN OVERSUBSCRIBED PRIVATE PLACEMENT FINANCING THAT IS EXPECTED TO RESULT IN TOTAL GROSS PROCEEDS OF APPROXIMATELY $30 MILLION TO THE COMPANY BEFORE DEDUCTING PLACEMENT AGENT FEES AND OTHER PRIVATE PLACEMENT EXPENSES (THE OFFERING).

APREA THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $30 MILLION PRIVATE PLACEMENT

CONFIRMED PARTIAL RESPONSE AT 220 MG INDICATES ANTI-TUMOR ACTIVITY OF APR-1051 IN BIOMARKER-DEFINED CANCERS EARLY CLINICAL DATA SUGGEST THE POTENTIAL OF APR-1051 AS A BEST-IN-CLASS WEE1 INHIBITOR EMERGING CLINICAL PROOF OF CONCEPT RESPONSES WITHOUT CLASS-LIMITING TOXICITY TO DATE SUPPORT APREA'S DEVELOPMENT STRATEGY OF DIFFERENTIATED WEE1 INHIBITION WITH AN IMPROVED THERAPEUTIC INDEX A FURTHER UPDATE FROM THE TRIAL IS EXPECTED IN THE SECOND QUARTER OF 2026 DOYLESTOWN, PA., MARCH 30, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY ANNOUNCED THE CONFIRMATION OF A PARTIAL RESPONSE (PR) IN ITS ONGOING ACESOT-1051 TRIAL EVALUATING APR-1051, A POTENT AND SELECTIVE WEE1 KINASE INHIBITOR.

APREA THERAPEUTICS HIGHLIGHTS POSITIVE EMERGING CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, WITH A CONFIRMED PARTIAL RESPONSE IN THE ONGOING PHASE 1 ACESOT-1051 TRIAL

DOYLESTOWN, PA., MARCH 16, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE PRECISION MEDICINE ONCOLOGY COMPANY FOCUSED ON THE DISCOVERY AND DEVELOPMENT OF TARGETED THERAPIES FOR PATIENTS WITH BIOMARKER-DEFINED CANCERS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

APREA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

TUMOR SHRINKAGE OF 50% AND SIGNIFICANT CA-125 BIOMARKER REDUCTION OBSERVED AT 220 MG DOSE LEVEL PATIENT EXPERIENCED ONLY GRADE 1 ADVERSE EVENTS REPRESENTS SECOND PATIENT WITH PR TO HARBOR PPP2R1A MUTATION, SUPPORTING MECHANISTIC THESIS OF TARGETING WEE1 FOR THIS PATIENT POPULATION EMERGING CLINICAL PROOF OF CONCEPT RESPONSES WITHOUT CLASS-LIMITING TOXICITY TO DATE SUPPORT APREA'S DEVELOPMENT STRATEGY OF DIFFERENTIATED WEE1 INHIBITION WITH AN IMPROVED THERAPEUTIC INDEX DOYLESTOWN, PA., FEB. 18, 2026 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC. (NASDAQ: APRE) (APREA OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES THAT EXPLOIT CANCER-SPECIFIC VULNERABILITIES WHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY ANNOUNCED ADDITIONAL PRELIMINARY DATA FROM THE ONGOING PHASE 1 ACESOT-1051 TRIAL EVALUATING ITS INVESTIGATIONAL WEE1 KINASE INHIBITOR APR-1051.

APREA THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE CLINICAL ACTIVITY FOR WEE1 INHIBITOR, APR-1051, INCLUDING SECOND PARTIAL RESPONSE IN ONGOING ACESOT-1051 TRIAL

Aprea Therapeutics, Inc.

APRE

Price

Financial Reports

No items found.

Press Releases

Aprea Therapeutics, Inc.

APRE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

APRE